Last reviewed · How we verify
NCT03830684
A Randomized, Double-blind, Placebo-controlled, Multicenter and Phase Ⅱa Clinical Trial for the Effectiveness and Safety of Baicalein Tablets in the Treatment of Improve Other Aspects of Healthy Adult With Influenza Fever
Phase 2 trial testing Baicalein Tablets 400mg in Influenza in 180 participants. Status unknown.
31 May 2019
Quick facts
| Lead sponsor | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 180 |
| Start date | 1 February 2019 |
| Primary completion | 31 May 2019 |
| Estimated completion | 31 October 2019 |
Drugs / interventions tested
- Baicalein Tablets 400mg — full drug profile →
- Baicalein Tablets 600mg — full drug profile →
- blank control 0mg — full drug profile →
Conditions studied
- Influenza — all drugs for Influenza →
Sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →
Who can join
Adults 18 to 65, any sex, with Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study in order to evaluate the Baicalein Tablets' safety and efficiency for audit with influenza
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Targeting ferroptosis opens new avenues for the development of novel therapeutics.
Sun S, Shen J, Jiang J, Wang F, et al · · 2023 · cited 380× · PMID 37735472 · DOI 10.1038/s41392-023-01606-1 -
Anti-SARS-CoV-2 activities in vitro of Shuanghuanglian preparations and bioactive ingredients.
Su HX, Yao S, Zhao WF, Li MJ, et al · · 2020 · cited 343× · PMID 32737471 · DOI 10.1038/s41401-020-0483-6 -
Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities.
Cannalire R, Cerchia C, Beccari AR, Di Leva FS, et al · · 2022 · cited 171× · PMID 33186044 · DOI 10.1021/acs.jmedchem.0c01140 -
Ferroptosis: mechanisms and therapeutic targets.
Zhou Q, Meng Y, Le J, Sun Y, et al · · 2024 · cited 32× · PMID 39568772 · DOI 10.1002/mco2.70010 -
Adenine overload induces ferroptosis in human primary proximal tubular epithelial cells.
Khan MA, Nag P, Grivei A, Giuliani KTK, et al · · 2022 · cited 31× · PMID 35110539 · DOI 10.1038/s41419-022-04527-z -
Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL).
Lu G, Jin S, Lin S, Gong Y, et al · · 2023 · cited 25× · PMID 37533111 · DOI 10.1186/s13148-023-01531-8 -
Human proximal tubular epithelial cell-derived small extracellular vesicles mediate synchronized tubular ferroptosis in hypoxic kidney injury.
Wang X, Kim CS, Adams BC, Wilkinson R, et al · · 2024 · cited 23× · PMID 38244399 · DOI 10.1016/j.redox.2024.103042 -
Possible Therapeutic Use of Natural Compounds Against COVID-19.
Khan N, Chen X, Geiger JD. · · 2021 · cited 23× · PMID 33768214 · DOI 10.33696/signaling.2.036
Verify or expand the search:
- PubMed search for NCT03830684
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Influenza
Currently open trials in the same condition.
- NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
- NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
- NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
- NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials
Trials by the same sponsor.
- NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
- NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
- NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
- NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
- NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03830684 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- Last refreshed: 5 February 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03830684.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing